Chapter 16
Polymorphisms of Drug Transporters and Their Clinical Implications
Cindy Q. Xia,
Johnny J. Yang,
Cindy Q. Xia
Department of DMPK, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
Search for more papers by this authorJohnny J. Yang
Department of DMPK, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
Search for more papers by this authorCindy Q. Xia,
Johnny J. Yang,
Cindy Q. Xia
Department of DMPK, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
Search for more papers by this authorJohnny J. Yang
Department of DMPK, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
Search for more papers by this authorBook Editor(s):Chuang Lu,
Albert P. Li,
Chuang Lu
Department of DMPK, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
Search for more papers by this authorAlbert P. Li
In Vitro ADMET Laboratories, Columbia, Maryland, USA
Search for more papers by this authorSummary
This chapter contains sections titled:
-
Introduction
-
Genetic Polymorphisms Of MDR 1 (P-gp) and their Implications
-
Genetic Polymorphisms of MRP and their Implications
-
Genetic Polymorphisms of BCRP and their Implications
-
Genetic Polymorphisms of OATP (SLC 21) and their Implications
-
Genetic Polymorphisms of OAT and OCT (SLC 22) and their Implications
-
Genetic Polymorphisms of PEPT (SLC 15) and their Implications
-
Summary
-
References
REFERENCES
- Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, Gross AS, Polli JW, Lou Y, Lee EJ. The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects. Br J Clin Pharmacol 2008; 66: 233–239.
- Allen JD, Jackson SC, Schinkel AH. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for doxorubicin resistance. Cancer Res 2002; 62: 2294–2299.
- Ambudkar SV. DS, Hrycyna CA, Ramachandra M, Pstan I, Gottesman MM. Biochemical, cellular and pharcological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361–398.
- Annese V, Valvano MR, Palmieri O, Latiano A, Bossa F, Andriulli A. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J Gastroenterol 2006; 12: 3636–3644.
- Asano T, Takahashi KA, Fujioka M, Inoue S, Okamoto M, Sugioka N, Nishino H, Tanaka T, Hirota Y, Kubo T. ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 2003; 13: 675–682.
- Backstrom G, Taipalensuu J, Melhus H, Brandstrom H, Svensson A-C, Artursson P, Kindmark A. Genetic variation in the ATP-binding Cassette Transporter gene ABCG2 (BCRP) in a Swedish population. Eur J Pharm Sci 2003; 18: 359–364.
- Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C, Sikic BI. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Nat Cancer Inst 1995; 87: 1593–1602.
- Bernsdorf A, Giessmann T, Modess C, Wegner D, Igelbrink S, Hecker U, Haenisch S, Cascorbi I, Terhaag B, Siegmund W. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharm 2006; 61: 440–450.
- Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002; 71: 537–592.
- Brumme ZL, Dong WWY, Chan KJ, Hogg RS, Montaner JSG, O'Shaughnessy MV and Harrigan PR. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS (London, U. K.) FIELD Full Journal Title: AIDS (London, United Kingdom) 2003; 17: 201–208.
- Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381–389.
- Chen Z-S, Robey RW, Belinsky MG, Shchaveleva I, Ren X-Q, Sugimoto Y, Ross DD, Bates SE, Kruh GD. Transport of methotrexate, methotrexate polyglutamates, and 17b-estradiol 17-(b-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 2003; 63: 4048–4054.
- Choi JH, Lee MG, Cho JY, Lee JE, Kim KH, Park K. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin Pharmacol Ther 2007; 83: 251–257.
- Chowbay B, Li H, David M, Cheung YB, Lee EJ. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 2005; 60: 159–171.
- Chung J-Y, Cho J-Y, Yu K-S, Kim J-R, Oh D-S, Jung H-R, Lim K-S, Moon K-H, Shin S-G, Jang I-J. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther (NY) 2005; 78: 342–350.
- Couvert P, Giral P, Dejager S, Gu J, Huby T, Chapman MJ, Bruckert E, Carrie A. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 2008; 9: 1217–1227.
- De Jong FA, Marsh S, Mathijssen RHJ, King C, Verweij J, Sparreboom A, McLeod HL. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on Irinotecan disposition. Clin Cancer Res 2004; 10: 5889–5894.
- Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003; 13: 259–263.
- Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, Herczynska M. The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol 2006; 62: 933–937.
- Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave J-P, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30–36.
- Furuno T, Landi M-T, Ceroni M, Caporaso N, Bernucci I, Nappi G, Martignoni E, Schaeffeler E, Eichelbaum M, Schwab M, Zanger UM. Expression polymorphism of the blood—brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 2002; 12: 529–534.
- Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood—brain barrier. J Pharmacol Exp Ther 2000; 294: 73–79.
- Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL, Jr, Donahue JP, Kim RB. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an adult AIDS clinical trials group study. J Infect Dis 2005; 192: 1931–1942.
- Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, Ackermann H, Seidl C, Hocher B, Zanger UM, Geiger H, Eichelbaum M, Schwab M. ABCB1 genotype of the donor but not of the recipient is a major risk factor for Cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16: 1501–1511.
- Hirouchi M, Suzuki H, Itoda M, Ozawa S, Sawada J, Ieiri I, Ohtsubo K, Sugiyama Y. Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm Res 2004; 21: 742–748.
- Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005; 78: 260–277.
- Hoffmeyer S, Burk O, Von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473–3478.
- Honjo Y, Hrycyna CA, Yan Q-W, Medina-Perez WY, Robey RW, Van de Laar A, Litman T, Dean M, Bates SE. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 2001; 61: 6635–6639.
- Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, Dean M, Bates SE. Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol Ther 2002; 1: 696–702.
- Ieiri I, Suzuki H, Kimura M, Takane H, Nishizato Y, Irie S, Urae A, Kawabata K, Higuchi S, Otsubo K, Sugiyama Y. Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects. Hepatol Res 2004a; 30: 91–95.
- Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 2004b; 43: 553–576.
- Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D, Schakel U, Ehninger G, Schaich M. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62: 4955–4962.
- Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002; 1: 611–616.
- Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001; 11: 175–184.
- Itoda M, Saito Y, Soyama A, Saeki M, Murayama N, Ishida S, Sai K, Nagano M, Suzuki H, Sugiyama Y, Ozawa S, Sawada Ji J. Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5′-untranslated region and exon 28. Drug Metab Dispos 2002; 30: 363–364.
- Jamroziak K, Balcerczak E, Cebula B, Kowalczyk M, Panczyk M, Janus A, Smolewski P, Mirowski M, Robak T. Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia. Pharmacol Rep 2005; 57: 882–888.
- Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta Biomembranes 1976; 455: 152–162.
- Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 2004; 93: 1046–1050.
- Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol 2008a; 48: 311–321.
- Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. Br J Clin Pharmacol 2008b; 65: 78–86.
- Kang H-A, Cho H-Y, Lee Y-B. The effect of MDR1 G2677T/A polymorphism on pharmacokinetics of gabapentin in healthy Korean subjects. Arch Pharmacol Res 2007; 30: 96–101.
- Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett (Amsterdam) 2006; 234: 4–33.
- Kioka N, Tsubota J, Kakehi Y, Komano T, Gottesman MM, Pastan I, Ueda K. P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries gly185 with an altered pattern of multidrug resistance. Biochem Biophys Res Commun 1989; 162: 224–231.
- Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanba E, Oshimura M, Terakawa N, Otsubo K, Mine K, Sugiyama Y. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 2005; 33: 94–101.
- Kotrych K, Sulikowski T, Domanski L, Bialecka M, Drozdzik M. Polymorphism in the P-glycoprotein drug transporter MDR1 gene in renal transplant patients treated with cyclosporin A in a Polish population. Pharmacol Rep 2007; 59: 199–205.
- La Porte CJ, Li Y, Beique L, Foster BC, Chauhan B, Garber GE, Cameron DW, van Heeswijk RP. The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir. Clini Pharmacol Ther 2007; 82: 389–395.
- Lang T, Hitzl M, Burk O, Mornhinweg E, Keil A, Kerb R, Klein K, Zanger UM, Eichelbaum M, Fromm MF. Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics 2004; 14: 155–164.
- Lankas GR, Cartwright ME, Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 1997; 143: 357–365.
- Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Clark AG, Herskowitz I, Giacomini KM. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 2002; 12: 395–405.
- Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005a; 78: 330–341.
- Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, Leake BF, Kim RB. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 2005b; 280: 9610–9617.
- Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 2005; 6: 115–138.
- Letschert K, Keppler D, Koenig J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 2004; 14: 441–452.
- Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R, Meade T, Sleight P, Collins R, Barton J, Bray C, Wincott E, Clarke R, Graham I, Simpson D, Warlow C, Wilcken D, Tobert J, Musliner T, Wilhelmsen L, Doll R, Fox KM, Hill C, Sandercock P, Peto R. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 2008; 359: 789–799.
- Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther (St Louis) 2004; 75: 13–33.
- Marzolini C, Tirona RG, Kim RB. Pharmacogenetics of drug transporters. Drugs Pharm Sci 2005; 156: 109–155.
- Michalski C, Cui Y, Nies AT, Nuessler AK, Neuhaus P, Zanger UM, Klein K, Eichelbaum M, Keppler D, Konig J. A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 2002; 277: 43058–43063.
- Mickley LA, Lee J-S, Weng Z, Zhan Z, Alvarez M, Wilson W, Bates SE, Fojo T. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 1998; 91: 1749–1756.
- Mihaljevic-Peles A, Bozina N, Sagud M, Rojnic Kuzman M, Lovric M. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog Neuro-Psychopharmacol Biol Psychiatry 2008; 32: 1439–1444.
- Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int J Cancer 2004; 109: 238–246.
- Morimoto K, Oishi T, Ueda S, Ueda M, Hosokawa M, Chiba K. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacokinet 2004; 19: 453–455.
- Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther (St Louis) 2004; 75: 415–421.
- Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, Okumura K. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther (St Louis) 2002; 71: 297–303.
- Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivistoe KT. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14: 429–440.
- Niemi M, Kivistoe KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. Letter to the editors: Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 2005; 59: 602–604.
- Niemi M, Kivistoe KT, Diczfalusy U, Bodin K, Bertilsson L, Fromm MF, Eichelbaum M. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet Genomics 2006a; 16: 565–568.
- Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther (NY) 2006b; 80: 356–366.
- Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003; 73: 554–565.
- Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J-I, Sai Y, Tsuji A, Yokoi T. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 2002; 302: 804–813.
- Ostrovsky O, Nagler A, Korostishevsky M, Gazit E, Galski H. Genotype and allele frequencies of C3435T polymorphism of the MDR1 gene in various Jewish populations of Israel. Ther Drug Monit 2004; 26: 679–684.
- Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006; 16: 873–879.
- Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I, Gawronska-Szklarz B. The MDR1 3425 polymorphism in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 2004; 42: 496–503.
- Rahi M, Heikkinen T, Hakkola J, Hakala K, Wallerman O, Wadelius M, Wadelius C, Laine K. Influence of adenosine triphosphate and ABCB1 (MDR1) genotype on the P-glycoprotein-dependent transfer of saquinavir in the dually perfused human placenta. Hum Exp Toxicol 2008; 27: 65–71.
- Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2002; 2: 191–196.
- Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, Litman T, Bates SE. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 2001; 1512: 171–182.
- Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S, Higuchi S, Nakamura Y. Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR). J Hum Genet 2002; 47: 147–171.
- Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, Starr S, Spector SA. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS (London) 2005; 19: 371–380.
- Sakaeda T. MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 2005; 20: 391–414.
- Sakata T, Anzai N, Shin HJ, Noshiro R, Hirata T, Yokoyama H, Kanai Y, Endou H. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun 2004; 313: 789–793.
- Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K, Ieiri I. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 2007; 52: 117–122.
- Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D, Kawamoto M, Johns SJ, DeYoung J, Carlson E, Ferrin TE, Herskowitz I, Giacomini KM, Benet LZ, Brett CM, Burchard EG, Castro R, de la Cruz M, Edwards RH, Gitschier J, Glatt CE, Ho C, Kroetz DL, Lin ET, Reus VI, Sadee W, Salazar M, Schaefer C, Sheiner LB, Tran C, Urban TJ, Vulpe C, Wright EM. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA 2003; 100: 5902–5907.
- Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422–1431.
- Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, Giacomini KM. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther (NY) 2008; 83: 273–280.
- Siddiqui A, Kerb R, Weale M, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003; 348: 1442–1448.
- Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, Brodie MJ. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 2005; 46: 643–647.
- Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resistance Updates 2003; 6: 71–84.
- Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, McLeod HL. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther (St Louis) 2004; 76: 38–44.
-
Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD, Nooter K, Gelderblom H. Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther 2005; 4: e7–e10.
10.4161/cbt.4.6.1731 Google Scholar
- Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 2004; 19: 375–380.
- Takano A, Kusuhara H, Suhara T, Ieiri I, Morimoto T, Lee YJ, Maeda J, Ikoma Y, Ito H, Suzuki K, Sugiyama Y. Evaluation of in vivo P-glycoprotein function at the blood—brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J Nuclear Med 2006; 47: 1427–1433.
- Tan NCK, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears DF, Mulley JC, Berkovic SF. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 2004; 63: 1090–1092.
- Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297: 1137–1143.
- Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, Lee CG. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations [see comment]. Pharmacogenetics 2002; 12: 437–450.
- Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C. Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001; 276: 35669–35675.
- Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 2003; 304: 223–228.
- Verstuyft C, Marcellin F, Morand-Joubert L, Launay O, Brendel K, Mentre F, Peytavin G, Gerard L, Becquemont L, Aboulker JP. Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS (Hagerstown, MD) 2005; 19: 2127–2131.
- Wang H, Hao B, Zhou K, Chen X, Wu S, Zhou G, Zhu Y, He F. Linkage disequilibrium and haplotype architecture for two ABC transporter genes (ABCC1 and ABCG2) in Chinese population: implications for pharmacogenomic association studies. Ann Hum Genet 2004; 68: 563–573 [erratum appears in Ann Hum Genet. 2005;69(Pt 4):499].
- Wang Z-J, Yin OQP, Tomlinson B, Chow MSS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 2008; 18: 637–645.
- Wang Z-Y, Chen L-H, Fan Q, Yan W-P, Chen Y-Q, Li Q-S, Yuan Y-W. Relationship between radiosensitivity of nasopharyngeal carcinoma and MDR1 gene polymorphism. Nanfang Yike Daxue Xuebao 2007; 27: 580–583.
- Winzer R, Langmann P, Zilly M, Tollmann F, Schubert J, Klinker H, Weissbrich B. No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment of naive HIV-positive patients. Ann Clin Microbiol Antimicrob 2005; 4: 3–9.
- Xia CQ, Milton MN, Gan L-S. Evaluation of drug-transporter interactions using in vitro and in vivo models. Curr Drug Metab 2007; 8: 341–363.
- Xia CQ, Yang JJ, Balani SK. Drug transporters in drug disposition, drug interactions, and drug resistance. In Drug Metabolism in Drug Design and Development. Zhang D, Zhu M, Humphreys WG, eds. Wiley-Interscience, 2008, pp. 137–203.
- Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, Ando Y, Irie S, Ware J, Nakai Y, Higuchi S, Sugiyama Y. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther 2008; 84: 95–103.
- Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R, Higuchi S, Otsubo K, Sugimachi K. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 2002; 74: 571–573.
- Yasui-Furukori N, Saito M, Nakagami T, Kaneda A, Tateishi T, Kaneko S. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog Neuro-Psychopharmacol Biol Psychiatry 2006; 30: 286–291.
- Zair ZM, Eloranta JJ, Stieger B, Kullak-Ublick GA. Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics 2008; 9: 597–624.
- Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, Schuetz EG. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003; 13: 19–28.
- Zhang W, Yu B-N, He Y-J, Fan L, Li Q, Liu Z-Q, Wang A, Liu Y-L, Tan Z-R, Fen J, Huang Y-F, Zhou H-H. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 2006; 373: 99–103.
- Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Lamba J, Bowman P, Burckart GJ. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 2002; 63: 765–770.
- Zheng HX, Webber SA, Zeevi A, Schuetz E, Zhang J, Lamba J, Boyle GJ, Wilson JW, Burckart GJ. The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis. Pediatr Transplant 2004; 8: 551–557.
- Zhou Q, Sparreboom A, Tan E-H, Cheung Y-B, Lee A, Poon D, Lee EJD, Chowbay B. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol 2005; 59: 415–424.
- Zhu D, Taguchi-Nakamura H, Goto M, Odawara T, Nakamura T, Yamada H, Kotaki H, Sugiura W, Iwamoto A, Kitamura Y. Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy. Antiviral Ther 2004; 9: 929–935.
